Beractant, with the CAS number 108778-82-1, is a pulmonary surfactant primarily used in the treatment of neonatal respiratory distress syndrome (RDS). It is derived from animal lung extract and contains a mixture of phospholipids, primarily dipalmitoylphosphatidylcholine, along with surfactant proteins. The primary characteristic of beractant is its ability to reduce surface tension in the alveoli, thereby improving lung function and facilitating gas exchange in premature infants whose lungs are not fully developed. This surfactant helps prevent alveolar collapse during expiration, enhancing lung compliance and oxygenation. Beractant is administered via intratracheal instillation and is typically well-tolerated, although potential side effects may include transient bradycardia or oxygen desaturation. Its efficacy in improving respiratory outcomes has made it a critical component in neonatal intensive care units for managing RDS. Overall, beractant plays a vital role in supporting the respiratory health of premature infants, significantly reducing morbidity and mortality associated with this condition.

Beractant

108778-82-1: Beractant, with the CAS number 108778-82-1, is a pulmonary surfactant primarily used in the treatment of neonatal respiratory distress syndrome (RDS). It is derived from animal lung extract and contains a mixture of phospholipids, primarily dipalmitoylphosphatidylcholine, along with surfactant proteins. The primary characteristic of beractant is its ability to reduce surface tension in the alveoli, thereby improving lung function and facilitating gas exchange in premature infants whose lungs are not fully developed. This surfactant helps prevent alveolar collapse during expiration, enhancing lung compliance and oxygenation. Beractant is administered via intratracheal instillation and is typically well-tolerated, although potential side effects may include transient bradycardia or oxygen desaturation. Its efficacy in improving respiratory outcomes has made it a critical component in neonatal intensive care units for managing RDS. Overall, beractant plays a vital role in supporting the respiratory health of premature infants, significantly reducing morbidity and mortality associated with this condition.

CAS 108778-82-1

Beractant